Inotiv (NOTV.Q) Aktienübersicht
Inotiv, Inc. bietet nichtklinische und analytische Dienstleistungen zur Erforschung und Entwicklung von Arzneimitteln für die pharmazeutische und medizintechnische Industrie in den Vereinigten Staaten, den Niederlanden und international an. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 2/6 |
| Künftiges Wachstum | 0/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
NOTV.Q Community Fair Values
Create NarrativeSee what 42 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Inotiv, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$0.05 |
| 52-Wochen-Hoch | US$2.44 |
| 52-Wochen-Tief | US$0.026 |
| Beta | 3.77 |
| 1 Monat Veränderung | -84.08% |
| 3 Monate Veränderung | -85.31% |
| 1 Jahr Veränderung | -97.75% |
| 3 Jahre Veränderung | -99.05% |
| 5 Jahre Veränderung | -99.83% |
| Veränderung seit IPO | -99.39% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.
Narrativ-Update • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.Recent updates
Narrativ-Update • Jun 03
NOTV: Future P/E And Margins Will Drive Upside Despite Bankruptcy
Analysts have updated their view on Inotiv with a revised $5.00 price target, citing refreshed assumptions for revenue growth, profit margins, discount rate, and future P/E, which collectively adjust the stock's risk and return profile without changing the headline valuation level. What's in the News Inotiv and multiple affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on June 3, 2026, with reported assets and liabilities each in the range of US$500m to US$1b.Narrativ-Update • May 15
NOTV: Improving Margins And Higher Future P/E Will Support Upside
Analysts have held their fair value estimate for Inotiv steady at $3.25, citing updated assumptions for revenue growth of 5.99%, a profit margin of 15.62%, a discount rate of 12.46% and a future P/E of 1.76x as key inputs behind the maintained target. Valuation Changes Fair Value: Held steady at $3.25, with no change in the model output.Narrativ-Update • Apr 29
NOTV: Refined Outlook Will Rely On Margin Execution And Future P/E
Narrative Update on Inotiv Analysts reduced their price target on Inotiv by $1.50, aligning the change with updated expectations for slightly different revenue growth, profit margin, and future P/E assumptions. Analyst Commentary The latest move to trim the price target by $1.50 reflects analysts fine tuning their models for Inotiv, with updated assumptions around revenue mix, profitability, and future P/E levels.Narrativ-Update • Apr 15
NOTV: Margin Execution And Higher Future P/E Will Support Upside
Analysts have trimmed their price target on Inotiv by $1.50 to reflect updated expectations for profit margins and a slightly higher assumed future P/E multiple. Analyst Commentary Recent research suggests that the trimmed price target reflects a recalibration of expectations rather than a complete shift in the investment case for Inotiv.
Narrativ-Update • Apr 01
NOTV: Future Upside Will Depend On Meeting Nasdaq Bid Price Requirement
Analysts have lowered their price target on Inotiv by $1.50 to reflect updated fair value estimates, a slightly adjusted discount rate, and modest changes to assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Bearish analysts lowering the price target by $1.50 are signaling a more cautious stance on how Inotiv is priced relative to updated fair value estimates.Narrativ-Update • Mar 18
NOTV: Refined Outlook Will Rely On Margin Execution And Nasdaq Compliance
Analysts have reduced their price target on Inotiv by $1.50, citing updated assumptions about slightly different revenue growth, profit margin and future P/E expectations, while maintaining their fair value estimate of $5.00. Analyst Commentary Even with the reduced price target, bullish analysts continue to see a path where the current fair value estimate of $5.00 is supported by Inotiv's revenue profile, margin potential and P/E framework.
Narrativ-Update • Mar 06
The Global Shortage of Research Primates and Why It May Matter for Inotiv
Non-human primates (NHPs), particularly cynomolgus macaques, remain one of the most important animal models in modern drug development. Their physiological similarity to humans makes them essential for evaluating safety, pharmacokinetics, and toxicity before new drugs enter human clinical trials.Narrativ-Update • Mar 04
The Hidden Scientific Infrastructure Behind Inotiv.
Introduction In recent years, Inotiv has frequently appeared in the news due to a series of challenges. These include regulatory issues related to the Envigo acquisition, global disruptions in non-human primate supply chains, debt inherited through acquisitions, and even a cybersecurity incident.Narrativ-Update • Mar 04
NOTV: AI Data Partnership Will Support Future Upside Despite Going Concern Risk
Analysts have reduced their price target on Inotiv by $1.58 to $3.25, citing updated assumptions around fair value, the discount rate, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Analysts cutting their target price to US$3.25 are essentially saying their expectations around Inotiv’s execution, growth profile, and risk level have shifted.Narrativ-Update • Feb 23
Why March 6 and March 31 Matter
— In Light of Inotiv, Inc.’s Eighth Amendment and Recent Institutional Disclosure In recent discussions surrounding Inotiv, Inc. (NASDAQ: NOTV), the dates of March 6 and March 31 have been frequently highlighted as important milestones.Narrativ-Update • Feb 17
NOTV: Recalibrated Outlook Will Rely On Execution And AI Collaboration
Analysts have reduced their price target for Inotiv by $4.00, citing updated assumptions on fair value, discount rate, revenue growth, profit margin and future P/E, which reflect a more cautious but still constructive view on the company. Analyst Commentary Bullish analysts are framing the lower price target as a recalibration of assumptions rather than a loss of confidence in Inotiv.Narrativ-Update • Feb 13
Inotiv's Margin Discipline Will Reshape Its Financial Future
Inotiv does not need perfection. It needs margin discipline.Neues Narrativ • Feb 11
Inotiv NAMs Test Center
Dear Inotiv, My name is Jong Ik Kwon, DVM , a graduate of Seoul National University College of Veterinary Medicine. Earlier in my career, I worked for Kwangdong Pharmaceutical as a Clinical Research Manager (CRM) for two years , where I gained direct experience in clinical development, regulatory processes, and pharmaceutical operations.Narrativ-Update • Feb 03
NOTV: Raised Fair Value Will Rely On AI Collaboration Execution
Analysts have raised their fair value estimate for Inotiv from $2.50 to $3.00, citing updated assumptions on revenue growth, profit margins and future P/E, even as they apply a slightly higher 12.5% discount rate. What's in the News On December 31, 2025, Inotiv received a Nasdaq notification that its common stock did not meet the Minimum Bid Price Rule of a US$1.00 closing bid for 30 consecutive business days, starting a 180 day window, to June 29, 2026, to regain compliance under Listing Rule 5550(a)(2) (Nasdaq notice).Narrativ-Update • Jan 20
NOTV: AI Data Collaboration Will Drive Upside Despite Going Concern Risk
Analysts have kept their Inotiv price target broadly steady, adjusting their fair value estimate to US$4.83. Small tweaks to profit margin and future P/E assumptions left their overall view largely unchanged.Narrativ-Update • Jan 06
NOTV: AI Collaboration And Margin Expansion Will Support Upside Despite Going Concern Risk
Analysts have kept their price target for Inotiv steady at US$4.83, reflecting unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Inotiv and VUGENE announced a collaboration to integrate VUGENE's cloud-based bioinformatics and computational platform into Inotiv's Discovery & Translational Sciences Division, aimed at more efficient analysis of complex biological data across epigenomic, proteomic, and other molecular datasets (Key Developments).Narrativ-Update • Dec 19
NOTV: Future Margin Improvements Will Support Upside Despite Going Concern Risk
Narrative Update on Inotiv Analysts have modestly raised their price target on Inotiv to approximately $4.83 per share, citing slightly improved long term profit margin expectations and a marginally more attractive future earnings multiple. What's in the News Auditor Ernst & Young issued an unqualified opinion on Inotiv's latest 10 K but raised substantial doubt about the company’s ability to continue as a going concern, highlighting liquidity and sustainability risks for investors (10 K filing).Narrativ-Update • Dec 05
NOTV: Future Margins And Legal Settlement Will Support Share Upside
Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.Analyseartikel • Jun 27
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 28% Share Price Slump
Inotiv, Inc. ( NASDAQ:NOTV ) shareholders won't be pleased to see that the share price has had a very rough month...Analyseartikel • May 03
Positive Sentiment Still Eludes Inotiv, Inc. (NASDAQ:NOTV) Following 29% Share Price Slump
Unfortunately for some shareholders, the Inotiv, Inc. ( NASDAQ:NOTV ) share price has dived 29% in the last thirty...Analyseartikel • Apr 25
Health Check: How Prudently Does Inotiv (NASDAQ:NOTV) Use Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Neues Narrativ • Apr 06
NHP Facilities And North American Optimization Will Secure Stability
Expanding the non-human primates client base and investments in facilities aim to stabilize revenue and enhance profitability through improved service offerings.Analyseartikel • Mar 11
Market Cool On Inotiv, Inc.'s (NASDAQ:NOTV) Revenues Pushing Shares 32% Lower
To the annoyance of some shareholders, Inotiv, Inc. ( NASDAQ:NOTV ) shares are down a considerable 32% in the last...Analyseartikel • Dec 06
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analyseartikel • Apr 26
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
The Inotiv, Inc. ( NASDAQ:NOTV ) share price has softened a substantial 57% over the previous 30 days, handing back...Analyseartikel • Mar 19
Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Feb 13
Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Inotiv, Inc. ( NASDAQ:NOTV ) shares have continued their recent momentum with a 34% gain in the last month alone...Analyseartikel • Dec 18
Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Those holding Inotiv, Inc. ( NASDAQ:NOTV ) shares would be relieved that the share price has rebounded 61% in the last...Analyseartikel • Dec 13
Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
It's been a sad week for Inotiv, Inc. ( NASDAQ:NOTV ), who've watched their investment drop 19% to US$2.55 in the week...Analyseartikel • Nov 21
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Aug 14
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Aktionärsrenditen
| NOTV.Q | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | -69.9% | -2.3% | -2.4% |
| 1Y | -97.7% | 7.3% | 21.5% |
Rendite im Vergleich zur Industrie: NOTV.Q unter dem Niveau der Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 7.3% erzielte.
Rendite vs. Markt: NOTV.Q hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 21.5 erzielte.
Preisvolatilität
| NOTV.Q volatility | |
|---|---|
| NOTV.Q Average Weekly Movement | 42.0% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von NOTV.Q war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: NOTV.QDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 25% auf 42% gestiegen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1974 | 1,996 | Bob Leasure | www.inotiv.com |
Inotiv, Inc. bietet nichtklinische und analytische Dienstleistungen zur Entdeckung und Entwicklung von Arzneimitteln für die pharmazeutische und medizintechnische Industrie in den Vereinigten Staaten, den Niederlanden und international an. Das Unternehmen ist in zwei Segmenten tätig: Discovery and Safety Assessment (DSA) und Research Models and Services (RMS). Das Segment DMS stellt wissenschaftliche Instrumente für die biowissenschaftliche Forschung und die dazugehörige Software her, die von Pharmaunternehmen, Universitäten, staatlichen Forschungszentren und medizinischen Forschungseinrichtungen im Rahmen der BASi-Produktlinie des Unternehmens genutzt werden.
Inotiv, Inc.'s Grundlagenzusammenfassung
| NOTV.Q grundlegende Statistiken | |
|---|---|
| Marktanteil | US$1.74m |
| Gewinn(TTM) | -US$86.97m |
| Umsatz(TTM) | US$507.36m |
0.0x
Kurs-Umsatz-Verhältnis0.0x
Kurs-Gewinn-Verhältnis Ist NOTV.Q zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NOTV.Q Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$507.36m |
| Kosten der Einnahmen | US$390.95m |
| Bruttogewinn | US$116.41m |
| Sonstige Ausgaben | US$203.38m |
| Gewinn | -US$86.97m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.49 |
| Bruttomarge | 22.94% |
| Nettogewinnspanne | -17.14% |
| Schulden/Eigenkapital-Verhältnis | 549.2% |
Wie hat sich NOTV.Q auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/06/12 20:59 |
| Aktienkurs zum Tagesende | 2026/06/11 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/09/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Inotiv, Inc. wird von 5 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |